In Silico Molecular Docking Analysis of α -Pinene: An Antioxidant and Anticancer Drug Obtained from *Myrtus communis*

Bahman Fazeli-Nasab ^{1,*}, Riyaz Z. Sayyed ² and Ali Sobhanizadeh ³

¹Research Department of Agronomy and Plant Breeding, Agricultural Research Institute, University of Zabol, Zabol, Iran

²Department of Microbiology, PSGVMP'S Arts, Science and Commerce College, Shahada, Maharashtra, India

³Department of Horticulture Science, University of Zabol, Zabol, Iran

*Corresponding author: Research Department of Agronomy and Plant Breeding, Agricultural Research Institute, University of Zabol, ZIP: 9861335856, Zabol, Iran, Tel/Fax; +98-5432240696, Email: bfazeli@uoz.ac.ir

Received 2019 January 22; Revised 2020 August 16; Accepted 2020 August 17.

Abstract

Background: Testis-specific protein on Y chromosome (TSPY) is the output of a tandem gene cluster. TSPY expression has been observed in gonadoblastoma and numerous distinct kinds of germ cell tumors, such as carcinoma in situ/intratubular germ cell neoplasia, seminoma, and extragonadal intracranial germ cell tumors (GCT). *Myrtus communis* extract rich in α -pinene showed high antioxidant and anticancer activity against a TSPY.

Methods: The molecular weight and theoretical isoelectric of the TSPY proteins were calculated, using the ExPASSY ProtParam tools. Some software like mega 6, BioEdit, NEB cutter (New England Biolabs), and CAP3 were used to analyze clustering and find restriction enzymes on the TSPY sequence. To evaluate the nucleotide diversity of all sequences, the number of diverse situations and Tajima's and Watterson's estimators of theta were assessed. Nucleotide polymorphism can be measured by several parameters, such as haplotypes diversity, nucleotide diversity, Theta using Dnasp software. To find interaction networks of protein-protein search tool for the retrieval of interacting genes/proteins (STRING) tools and to predict 3D structure, SWISS-MODEL was used; however, for docking protein-peptide based on interaction, Swiss Dock, Galaxy web, and CABS-dock software were employed.

Results: We report a high (0.91) dN/dS index, positive Tajima's D, Fu, and Li's tests, and a non-significant D test suggesting the occurrence of old modifications or a decrease of newborn mutations in the TSPY gene family. Interestingly, several hub proteins produced a strong chain or an operative module within their protein groups, such as nucleosome assembly protein (1NAP1L), RBMXL2, TBL1Y, and AMELY, which are all associated with the same cellular appliance elements and/or genetic uses. The docking of the TSPY target with α -pinene using docking revealed that the computationally-prognosticated lowest energy networks of TSPY are established by intermolecular hydrogen bonds and stacking interactions.

Conclusions: The results of this study demonstrated that α -pinene interacts with the TSPY protein target and could be developed as a promising candidate for the new anticancer agent.

Keywords: TSPY, Alpha-Pinene, Carcinoma, Seminoma, *Myrtus*

1. Background

The human Testis-specific protein on Y chromosome (TSPY) is a multi-copy gene, and its genetic interactions have been clinically correlated with gonadoblastoma (1). The TSPY gene has been initially identified as a Y-linked gene specifically expressed in the testis and it is tandem repeated in 20.3 kb highly homologous units, usually in the range of 21 to 35 copies, on the short arm of the Y chromosome (2, 3). TSPY is a member of SE (Su [var]3-9, Enhancer of zeste) translocation (Su [var]3-9, Enhancer of zeste and Trithorax) (SET)/NAP1 superfamily harboring a highly homologous SET/NAP-domain, originally recognized in the

SET oncoprotein and the NAP1 (4).

The human TSPY is revealed in gonocytes in the immature testis (5), spermatogonia, and prophase I spermatocytes at preleptotene to zygotene stages in adult testis (6). Indeed, TSPY expression has been observed in gonadoblastoma, and numerous distinct kinds of germ cell tumors (GCT), such as carcinoma in situ/intratubular germ cell neoplasia unknown (CIS/ITGCNU) (the precursor for all Testicular GCTs [TGCTs]), seminoma, and extragonadal intracranial GCT. TSPY protein is a significant marker that executes a function in the pathogenesis of TGCTs. It was also approved that 27 genes have been mapped on the human Y chromosome that encodes proteins or non-coding RNAs

(ribonucleic acid) (2). TSPY appears conserved among animals (7, 8). Nevertheless, identification of its physiological influence has been difficult because standard homologous recombination is embarrassed by various repeated sequences and multi-copy genes on the Y chromosome. Though, the TSPY gene is identified to be linked with the locus for gonadoblastoma (9, 10).

It is mentioned that the venture of testis cancer was increased by the possession of several characteristics linked with exposure of the testis to heat like getting exposed to fertilizers, phenols, and fumes or smoke and trauma to the testis (11).

Unlike most other tumors, testicular cancer is the most usual malice in men aged 15 to 34 years; it is estimated 1% of all cancers in people. While in the last decade, testicular cancer has significantly progressed (12). Its occurrence is much higher (4 times more) than in black people (12, 13). However, the preponderance of testicular cancers is healable even at forward steps (12).

The majority of the available anticancer drugs (more than 3000 drugs) are obtained from natural sources (plants) (14-16). Out of 121 medicines that are being used today for cancer therapy, 90 of them are of plant origin and approximately 75% are identified from traditions claims (17). Natural outputs have been the only most fertile source of leads for the expansion of medicines (18). Some of the medicinal plants that are widely used as a source of anticancer drugs in Iran include seed of *Carum carvi* L. (general anticancer), leaves and flowers of *Brassica oleracea* L. (uterus and skin cancer treatment), fruit cooked and lotion of *Cucurbita maxima* Duchesne (internal organs cancer treatment), powder and decoction of aerial parts *Cuscuta epithymum* L. and fruit and fruit peel juice of *Punica granatum* L. (ulcerating tumor treatment), gum of *Acacia nilotica* (L.) Delile (eye cancer treatment), cooked fruit of *Ficus carica* L. (general anticancer), and dust powder of wood of *Salix aegyptiaca* L. (skin cancer treatment) (19).

Plant-derived terpenoid components are identified to defeat nuclear factor- κ B (NF- κ B) signaling, the important regulator in the pathogenesis of passionate infections and tumors (20). Interestingly, useful components in some plant-derived curative essences are also terpenoid composites of monoterpenoid, sesquiterpenoid, diterpenoid, triterpenoid, and carotenoid groups (20). Terpenoids are natural inhibitors with anti-inflammatory and anticancer potential having some materials, such as α -pinene (20). Also, the α -pinene is a natural compound that was isolated from different plants such as pine needle (21), *Schinus terebinthifolius* Raddi (Anacardiaceae) (15), which have shown

anticancer activity and anti-metastatic protection.

The last few decades have witnessed significant development in the utility of curative crops as a source of clinically useful anticancer agents with fewer side effects (22-24). However, the systematic studies on their mode of action and molecular docking analysis of anticancer drugs are scarce and need to be fully explored.

2. Objectives

The present study was undertaken for in silico molecular docking analysis of α -pinene as an anticancer drug against a TSPY.

3. Methods

3.1. TSPY Gene and Sequences Analysis

TSPY gene family used in the present study was obtained from the National Center for Biotechnology Information (NCBI) (Table 1). After receiving all sequences, repeat sequences were removed and eventually confirmation of the presence conserve domain of the TSPY gene family in the deoxyribonucleic acid (DNA) and protein sequences were identified, using the conserved domain database (CDD) database (25).

The molecular weight and theoretical isoelectric pH of the TSPY proteins were calculated, using the ExPASy ProtParam tool (26). The cellular status of proteins was identified by using the protParam program (27).

Codon sites included were 1st + 2nd + 3rd + Noncoding. All sites including gaps and missing data were discarded. The analysis of the whole of base replacements per position between sequences was conducted, using the maximum composite likelihood model (28).

Clustering analysis was carried out by using mega 6 software (29), a consensus sequence was created by BioEdit (30), restriction enzymes on the TSPY DNA sequence were located with the help of NEB cutter V2.0 (31), and TSPY DNA sequences were assembled by using CAP3 sequence assembly program (32). Besides nucleotide diversity of all sequences, the number of diverse positions, and Tajima's and Watterson's estimators of theta were measured. Tajima's D was also used to resolve if the TSPY genes in these taxa resulted in neutrally. Tajima's Neutrality Test (33) was conducted and the evolutionary analyses were analyzed in MEGA6 (29). Tajima's D, Fu and Li's D^* , F^* , D (named D^F), and F statistics were used for producing the information from

Table 1. Properties of the TSPY Gene Sequence Used in the Present Study

Accession Number	Properties
NM001197242.2	Human TSPY1 transcript variant 2 mRNA
NM001320962.1	Human TSPY10 transcript variant 2 mRNA
U58096.1	Human TSPY mRNA complete cds
NM_003308.4	Human TSPY1 transcript variant 1 mRNA
NM_001282469.2	Human TSPY10 transcript variant 1 mRNA
NM001243721.1	Human TSPY8 mRNA
NM001164471.1	Human TSPY4 mRNA
AY130858.1	Human TSPY encoded protein mRNA complete cds alternatively spliced
BC121114.1	Human TSPY3 mRNA complete cds
BC075016.2	Human TSPY3 mRNA complete cds
BC148425.1	Synthetic construct Human TSPY2 mRNA encodes a complete protein
AB464293.1	Synthetic construct DNA Human TSPY2 gene without stop codon in Flexi system
NM001320964.1	Human TSPY1 transcript variant 3 mRNA
BC121113.1	Homo sapiens similar to TSPY2 mRNA complete cds
M98524.1	Human TSPY gene exons 1 through 6
AF106331.1	Human TSPYq1 gene complete cds
NG009742.2	Human TSPY7 pseudogene (TSPY7P)
X74029.1	Human TSPY gene
M94893.1	Human TSPY mRNA 3 end clone pJA923
NG009702.2	Human TSPY6P
NG021936.1	Human TSPY9P
NG003077.4	Human TSPY11P
M94892.1	Human TSPY/CYS14 gene complete cds clone pJA36B2
NG016162.2	Human TSPY15P
NG003079.4	Human TSPY13P
NG003093.4	Human TSPY5P
NG003078.4	Human TSPY12P

only intraspecific data, whereas Fu and Li's DF and F statistics utilize information from the number of recent variations; the latter, therefore, requires the presence of an out-group to be computed.

Nucleotide polymorphisms were measured by parameters, such as haplotypes (genes) diversity, nucleotide diversity, and the number of separating positions (34-36), and its standard deviation (SD) was evaluated by theta (θ). These parameters were estimated by Dnasp software version 6.10.01 (37).

The number of diverse positions, Tajima's estimator of theta (π) (38) and Watterson's estimator of theta (36) were

calculated, using Mega 6 software (29). Where π is determined as the median number of nucleotide diversity between two sequences (38), Theta quantifies the level of variability as the total number of diversity positions (36). Both estimators were separated by the arrangement length to get the comparable values per nucleotide.

3.2. Nucleotide Diversity (θ)

Nucleotide diversity (θ) was evaluated by the method reported by Halushka et al. (39).

$$\theta = \frac{K}{aL} \quad (1)$$

$$a = \sum_{i=2}^n \frac{1}{i-1} \quad (2)$$

Wherever K is the number of SNPs distinguished in an alignment length, n is alleles and L is the total length of the sequence (bp).

3.3. Identification of Haplotypes

Classifying haplotypes for examining the genetic diversity of populations was taken, using the Chi-square experiment. This was based on allele frequencies in samples from various positions (40). Polymorphism and haplotype differentiation were analyzed, using Dnasp V6.10.01 (41). Sequences were further subjected to Tajima's Neutrality test (33).

3.4. Molecular Docking Analysis

To know the structural basis of protein target specificity, a computational ligand-target docking procedure was used to investigate the structural groups of the TSPY (target) with α -pinene (ligand). Initially, the protein-ligand attraction was studied for hydrophobic/hydrophilic characteristics of these groups by platinum software web server. Finally, protein-protein interaction networks of TSPY protein by STRING v10 (42) were used to predict the 3D structure of TSPY SWISS-MODEL (43) and for docking protein-peptide based on the interaction similarity, Swiss Dock (44), Galaxy web (45), and CABS-dock (46) were used. The energy of the interaction of α -pinene with the TSPY is attached "grid point." At each step of the simulation, the energy of interaction of ligand (α -pinene) and protein (TSPY) was estimated by applying atomic affinity potentials calculated on a grid by Galaxy web online software. The left parameters were anchored as default.

Beyond the use of experimental data, prediction accuracy can also be improved by integrating docking tools with other computational techniques, such as molecular

dynamics-based approaches (47, 48), key interactions (49), and prediction of the binding site (50); molecular dynamics was done by FG-MD server (51).

3.5. Model Validation

The accuracy of a predicted model and its stereochemical properties was evaluated by PROCHECK-NMR (52, 53). The model was selected based on various factors such as the overall G-factor, the number of residues in core allowed, generously allowed, and disallowed regions in the Ramachandran plot. The model was further analyzed by WHATIF (52), qualitative model energy analysis (QMEAN) (54), and protein structure analysis (ProSA) (55). ProSA was used for the display of Z-score and energy plots. Template modeling score (TM-score) and root mean square deviation (RMSD) by TM-score online (56, 57) as well as RMSD and atoms by SuperPose version 1.0 (58) were used to predict protein structure and docking.

4. Results

4.1. Estimation of Evolutionary Divergence between Sequences

After receiving all sequences, alignment was conducted; then, repeat sequences were removed and, finally, to confirm major counting of TSPY gene family, the presence of conserved domain of TSPY gene was surveyed and major open reading frame (ORF) was found in this counting and, then, was surveyed for the presence of conserved domain in the protein sequence. Following the confirmation of the presence of conserved domain, nucleotide composition and frequencies of TSPY gene sequences and comparative values of instantaneous r should be examined when estimating them. For simplicity, a sum of r values was 100 and the nucleotide frequencies obtained were A = 24.13%, T/U = 20.51%, C = 24.80%, and G = 30.55 %. For the calculation of maximum likelihood (ML) values, a tree topology was automatically calculated. The maximum log-likelihood for this computation was -3166.720. The numbers of nucleotide substitutions per position among sequences are presented in Table 2. More transitional substitution (15.79) was obtained between A and G and the less transitional substitutions (11.90) were found between C and T nucleotide. More transversions substitution (6.94) was obtained between T and G and C and G and fewer transversions substitution (4.66) was found between A and T and G and T nucleotide (Table 3). dN/dS index was 0.91.

The investigation involved 27 nucleotide sequences. Codon sites included were 1st + 2nd + 3rd + noncoding. All sites including gaps and missing data were discarded.

Table 2. Results of Tajima's Neutrality Test (33)

Variables	Values
m	27
S	385
p_s	0.574627
θ	0.149083
π	0.213463
D	1.709580 ^a
Haplotype/Nucleotide Diversity	
Number of haplotypes	25
Haplotype (gene) diversity	0.994
Medium number of nucleotide diversity	143.01994
Theta (per sequence) from Eta	114.15467
Theta (per site) from Eta	0.17038
Neutrality tests	
Fu and Li's D* test statistic	0.43428 ^a
Fu and Li's F* test statistic	0.733 ^a
Fu's Fs statistic	0.504
Strobeck's S statistic	0.659

Abbreviations: m, number of sequences; n, total number of sites; S, number of segregating sites; p_s, S/n; θ, p_s/a; π, nucleotide diversity (per site); and D is the Tajima test statistic ((59) for details)

^aNon-significant.

There were 670 sites in the final dataset. Based on the analysis of all sequences, 3819 identification sites were obtained. The total number of positions (excepting situations with gaps/missing data) was 670 (variable polymorphic sites were 385 and invariable monomorphic sites were 285; sites with alignment gaps or missing data were 3149; the number of haplotypes was 25 with a haplotype diversity index of 0.99 and Singleton number and counting were 56 and 6, respectively).

Levels of nucleotide difference overall loci were low (56 single-nucleotide diversity in < 4 kb of sequence) and substantially differed between any locus (Table 2). The rest of the traits like Theta (per sequence) from Eta, Theta (per site) from Eta, Fu's Fs statistic, and Strobeck's S statistic are shown in Table 2. Traits such as Tajima's D, Fu, and Li's D* test statistic and Fu and Li's F* test statistic were positive and none-significant.

TSPY gene analysis revealed the presence of two conservation sequences: Region_1 from 1101-1362 bp with the following sequence:

GRC YGT RCY KGG YSC YRG RSM BRY DRY BSC AGR RTY
YVT GYV YBG CGW GGR KCK GSY RGC HCA GRY YW GGT GGA
GCT GGA GCC RGT TAA TGC CYR AGC YAR GAA GGC STT TTC

Table 3. Maximum Likelihood Estimate of Substitution Matrix ^a

	A	T/U	C	G
A	-	4.66 ^c	5.64 ^c	15.79 ^b
T/U	5.48 ^c	-	14.38 ^b	6.94 ^c
C	5.48 ^c	11.90 ^b	-	6.94 ^c
G	12.48 ^b	4.66 ^c	5.64 ^c	-

^a Every record is the possibility of the replacement (r) from individual nucleotide (row) to the different nucleotide (column). The replacement model and valuations were determined following the Tamura-Nei (1993) model (60).

^b Valuations of various transitional replacements

^c Valuations of transversional replacements

TCRSCA GHG GGA AAA GMT GGA RNR GAG GYR CAA GYC SCR SCT RKR CYG SAS AGG GCG MCR TCA TYC AGR RCR TCC CTG GCT KCT GGG CCM ATG KTR WWW SCW WHY CAS YRY YYY WKM KGY CWK YCY WGW KSA SWG RYG MWS WYG RRR A

and Region 2 was from 1474-1558 bp with the following sequence:

RKW DTM MWG YRW KYV SCA RDG AAW MYC TKT SGT GAW GCC DAR CMK CAS ABR WTW YRS GGC WTC WYW TTS VAS WSC AGA AKY GAG T

ORF (section B) of the TSPY gene family sequence (E value: 0.00297)

4.2. In Silico Analysis

A consensus sequence was calculated in all TSPY gene sequences, using Bio-Edit sequence alignment editor 7 (30) software and, then, entered on the Neb-cutter site (<http://tools.neb.com/NEBcutter2/>) to identify specific restriction enzymes that can detect haplotypes. The results showed that numerous restriction enzymes could cut in the replicated region; a total of 5 types of restriction enzymes (PluTI, HaeII, XcmI, Apol, and BmrI) that could cut and split in a proliferative region in different samples were observed (Table 4).

4.3. Cluster Analysis

A neighbor-joining phylogenetic tree based on the simple matching distance clustered the 27 TSPY gene sequences into 3 major and separate groups, namely A (A1 and A2), B, and C (Figure 1). Based on the results of cluster analysis and Tajima's neutrality test, TSPY was found to be controlled using 3 group gene families with different alleles. W08050 (expressed in mouse), AA403245 (expressed in the fetus), and AA403239 (expressed in the fetus) TSPY genes are similar to the Q01534 gene. The present research also reported that W08050 and AA403245 are similar to Q01534 and stay on one group (subgroup A1), but AA403239 is a little different and stays on subgroup A2. Thus, these accession numbers are two alleles of one gene from TSPY. On

the other hand, the placement of the expressed genes in mouse and fetus into one group was shown to have some of TSPY genes expressed at certain stages of growth that they are different from other genes from another stage of growth.

According to NCBI data, AA725833, AI138810, AI005498, AI002165, AI001787, AA993340, AA608988, AA399368, and AA401773 accession number of TSPY gene are similar to M98524. However, in the present study, it was found that the only AA401773 is similar to the M98524 gene and, thus, it can be concluded that AA401773 and M98524 sequences are different alleles from one gene and others are alleles in another TSPY gene. Also, A725833, AI138810, AI005498, AI002165, AI001787, AA993340, AA608988, AA399368, and NG003078 are similar and it can also be concluded that these sequences are the same allele from one TSPY gene.

4.4. Principal Coordinates Analysis

To investigate the dispersion, distance, and evolutionary relationships among the TSPY gene sequences under study, their bi-plots were analyzed based on principal component analysis (PCA), and the first 3 components were depicted by software DARwin6 0.12 (61). The share of the first 3 components was 82.95%, 3.89%, and 2.03%, respectively, and in total, 88.87% of the total data. These values indicate that the first 3 components have been able to accurately calculate a high percentage of variation. According to the results, the TSPY genes sequence was divided into 4 groups, and also it was largely indicative of cluster analysis.

After the alignment of TSPY gene sequences, major ORF and, then, the secondary structure of this ORF were predicted (Figure 2A and Figure 3B). The Ramachandran diagram (62) for the second structure of the TSPY gene shows that this structure is good stroke chemistry and 91.3% of the remaining groups are in the red zone, which has the highest acceptability. It has several amino acids (324), with formula; C₁₆₁₉H₂₅₅₀N₄₇₂O₄₉₃S₁₄, a molecular weight of

Table 4. Restriction Enzymes with the Ability to Produce Polymorphic Bands in the TSPY sequences

Enzyme Name	Number cut	The Size of Polymorphic Bands (nt)	Restriction Site
PluII	1	1272	5'...GGCGC▼C...3'
		2547	3'...C▲CGCGG...5'
HaeII	1	1272	5'...RGC GC▼Y...3'
		2547	3'...Y▲CGCGR...5'
XcmI	1	1286	5'...CCANNNNN▼NNNTGG...3'
		2533	3'...GGTNNNN▲NNNNNACC...5'
ApoI	1	2836	5'...R▼AATTY...3'
		983	3'...YTTAA▲R...5'
BmrI	1	3245	5'...ACTGGG(N)5▼...3'
		574	3'...TGACCC(N)4▲...5'

Figure 1. Dendrogram comparison of TSPY genes sequences based on Clustal W methods using mega 6 software

36963.76 D, theoretical pI of 5.56. The amino acid composition was Ala (A), 10.2%, Arg (R) (9.0%), Asn (N) (3.7%), Asp (D) (3.1%), Cys (C) (1.2%), Gln (Q) (5.2%), Glu (E) (12.3%), Gly (G) (5.2%), His (H) (2.5%), Ile (I) (3.1%), Leu (L) (8.6%), Lys (K) (3.7%), Met (M) (3.1%), Phe (F) (3.4%), Pro (P) (5.2%), Ser (S) (6.2%), Thr (T) (2.8%), Trp (W) (1.2%), Tyr (Y) (3.1%), Val (V) (7.1%), Pyl (O) (0.0%), Sec (U) (0.0%), (B) (0.0%), (Z) (0.0%), X (0.0%), total number of negatively-charged residues (Asp + Glu) (50), total number of positively-charged residues (Arg + Lys) (41), Atomic composition; Carbon (1619), Hydrogen (2550), Nitrogen (472), Oxygen (493), Sulfur (14), Aliphatic index (76.51), and Grand average of hydropathicity (GRAVY) (-0.571). Integral prediction of protein location is shown in Table 5.

4.5. Gene Ontology Annotations and Protein Interaction Network Investigation

The review of considered influential factors that consist of proteins coded by the numerous expressed genes, direct and indirect interactions among these proteins inferred doing the STRING research tool gave protein interaction network files based on previously-reported communications between proteins. STRING mapping profiles of TSPY protein interaction network represented in Figure 4 depicts the number of nodes (11), the number of edges (17), average node degree (3.09), average local clustering coefficient (0.923), expected number of edges (10), and PPI enrichment P-value (0.0337). Interestingly, multiple hub proteins built a strong network or an operative module within their protein groups, such as nucleosome assembly protein 1-like (NAP1L) 1, 2, 4, 5, and 6 and also RNA binding motif protein, X-linked-like 2 (RBMXL2), transducin (beta)-like 1 (TBL1Y), and amelogenin, Y-linked (AMELY), which are all associated in the similar cellular appliance elements and/or genetic functions.

Among all the proteins in the STRING databases, those were core-connected and had higher expression in many experimental data in the regulatory interaction network. Nucleosome assembly protein 1-like may be implicated in modulating chromatin configuration and contribute to the regulation of cell reproduction and also TBL1Y protein associated with the employment of the ubiquitin/19S proteasome organize to nuclear receptor-regulated transcription factors that operate an imperative role in transcription activation mediated by nuclear receptors. Seemingly behaves as a fundamental element of co-repressor complexes that mediates the recruitment of the 19S proteasome complex, leading to the following proteasomal degeneration of transcription repressor groups, through

providing cofactor replacement (by analogy) (42), nucleosome arrangement proteins (63) are interested in moving histones into the nucleus, nucleosome machine, and chromatin fluidity and influence the transcription of many genes. The protein encoded by this intronless gene that it is a member of the NAP family represents a group of tissue-specific factors that regulates neuronal cell generation by interacting with chromatin (64).

4.6. In Silico Docking Analysis

Docking interaction between the ligand and the macromolecule (Figure 2B, C, and D) revealed the combination of TSPY and its binding (α -pinene) position and the aromatic groups as less hydrophilic. These interactions are vital to rank the molecular docking and matching between target and medicines. The hydrophobicity mappings were carried out to investigate the improvement of hydrophobicity clusters on the membrane surface along the molecular dynamics run and the features of interface among the membrane and membrane binding molecule.

It should be noted that in the structure of both α -pinene and TSPY proteins, there are various groups including aliphatic (lipid) and hydrophilic groups and this ability gave the protein *Myrtus communis* to be readily assisted by aliphatic groups of the membrane. The cell passes through the cytoplasm of the host cell and, with the help of hydrophilic groups, is soluble in the host cell cytoplasm and easily deactivates the TSPY protein.

Protein pairs with a TM-score > 0.5 are mostly in the same fold, while those with a TM-score < 0.5 are in a different fold (TM-score) (57). Several studies have suggested that the magnitude of RMSD, Global Distance Test (GDT-score), etc. are dependent on protein length (56), whereas the magnitude of TM-score is protein length-independent that is the expression of the P-value as a sole function of TM-score (57). The average TM-score value and the deviation with proteins of different sizes (from 80 to 200 amino acids) confirmed the size independence of the TM-score values in random protein pairs. The ligand is fully integrated with the A and B chains. Figure 3 shows the position of chemical bonds between the A, B, and ligand chains (Figure 3A) and the final structure of the docked protein (B) (Figure 3B).

In this research, we used both TM-score and RMSD to predict protein structure and docking (56, 57). The highest values of global and local root mean square deviation (RMSDs) (2.076 kJ/mol), Alpha Carbons (4.38 kJ/mol), GDT-TS-score (0.9436), GDT-HA-score (0.9211), Backbone (4.347 kJ/mol), and heavy atoms (5.147 kJ/mol) were obtained

Figure 2. Structure homology-modeling (3D Structure of TSPY protein [section A] and 3D complex docking of α -pinene with TSPY protein [section B, C, and D]).

Table 5. Integral Prediction of Protein Location

Location Weights	LocDB	Pot Loc DB	Neural Nets	Pentamers	Integral
Nuclear	10.0	3.0	1.13	0.00	9.94
Plasma membrane	0.0	0.0	0.08	0.18	0.01
Extracellular	0.0	0.0	0.08	0.34	0.00
Cytoplasmic	0.0	0.0	1.91	0.00	0.00
Mitochondrial	0.0	0.0	0.15	0.66	0.00
Endoplasm retic	0.0	0.0	0.02	0.00	0.00
Peroxisomal	0.0	0.0	0.06	0.00	0.00
Lysosomal	0.0	0.0	0.02	0.07	0.00
Golgi	0.0	0.0	0.04	1.91	0.05
Vacuolar	0.0	0.0	0.00	0.03	0.00

for TSPY model (Figure 5A and B) (Table 6). The docking of the TSPY target with α -pinene utilizing the docking method showed that all the computationally prognosticated lowest energy complexes of TSPY are preserved by

intermolecular hydrogen bonds and stacking interactions, from which we choose the first one. Protein structural with the highest values of global and local root mean square deviation RMSD (2.657), TM-score (0.871), GDT-TS-score (0.812),

Figure 3. The position of chemical bonds between the A, B, and ligand chains (A) and the final structure of the docked protein (B).

Figure 4. String mapping profiles of protein interaction network stewarding TSPY protein interactions. The protein interacting gene products are designated in blue and green lines. There are wholly 10 hub proteins recognized and many hub proteins designed a tight network or a working module within their protein families.

GDT-HA-score (0.655) (56, 57) was obtained for docking of α -pinene with TSPY model (Figure 5C, D, and E) (Table 7). The α -pinene ligand reflected the best interaction with target proteins. Docking results suggested that this α -pinene compound can enter the substrate-binding region of the active site. Finally, the results demonstrated that α -pinene accurately interacts with the TSPY protein target.

5. Discussion

Tajima's D is the total of an inequality word with uninterested type plus words that gives concrete weight to the antique waiting times and uninterested weight to the original ones. Therefore, Tajima's D is large and positive when there are long arms near the root. It is strongly negative when the dendrogram is biased and/or when original arms

Figure 5. Visualization of TM-score superposition for TSPY model and also docking of α -pinene with TSPY; A, Cartoon representation (Structure-1 in blue and Structure-2 in red); B, Str-1 in thick and Str-2 in thin wireframes (Residues with $d < 5\text{\AA}$ in red); C, The root mean square deviations (RMSD) as functions of the dock of α -pinene with TSPY model was achieved by SuperPose (65); D, Cartoon representation (Structure-1 in blue and Structure-2 in red); E, Str-1 in thick and Str-2 in thin wireframes (Residues with $d < 5\text{\AA}$ in red).

Table 6. RMSD and Atoms for Two Chains (A and B) of TSPY Model (58)

	Alpha Carbons	Back Bone	Heavy	All
RMSD	2.79	2.78	3.59	3.59
Atoms	188	752	1576	1576

are extended. Tajima's D is, thus, susceptible to both biased dendrograms and dendrograms with long branches near to the leaves (when negative) and balanced dendrograms with long branches near the root (when positive). The former is typical dendrograms for recently increasing groups or loci under directional selection and the latter is typical under balancing selection or for structured groups (66). In this research, Tajima's D was positive, non-significant, and

more than one (1.1709) (Table 2) and based on the tree (Figure 1) of TSPY gene family, it exhibits long branches close to the root; thus, it can be inferred that this result is true and also when there is an excess of old mutations or a reduction of young mutations, Tajima's D and the several tests by FU and LI (34) tend to be positive. It can, therefore, be concluded that the TSPY gene family has had the slightest changes during evolution, and what caused the changes

Table 7. RMSD and Atoms for two Chains (B with C and A with C) of the Dock of α -Pinene with TSPY Model (58)

	Alpha Carbons	Back Bone	Heavy	All	Structure	Residues
B with C						
RMSD	13.81	13.76	13.83	13.83	PDBA chain 'B'	223 - 229, 240 - 245, 250 - 266
Atoms	30	120	171	171	PDBB chain 'C'	1 - 7, 8 - 13, 14 - 30
A with C						
RMSD	12.93	12.88	12.99	12.99	PDBA chain 'A'	225 - 229, 240 - 242, 250 - 271
Atoms	30	120	157	157	PDBB chain 'C'	1 - 5, 6 - 8, 9 - 30

and the creation of new alleles result from mutations that occurred in the past and perhaps was one of the reasons for the earlier treatment of testicular cancer compared with other cancers. There are no new changes in the genes involved in the development of testicular cancer and whatever that has caused these types of genes to have occurred in the past happened.

In comparison with the nucleotide variations that have no impact on the resulting amino acid (dS), the results of the nucleotide variations that alter the amino acids (dN) can be a more useful and highly efficient method for the detection process of natural selection during genetic evolution. If the ratio is greater than one, the selection is positive, if it is less than one, it is a pure selection, and if it equals one, it will show a neutral selection during the evolution of these genes (67). In this study, the numerical value of the ratio (dN/dS) was 0.31, which was less than one, indicating that the pure selection has occurred on the desired gene without any key changes. NAP-1 participates in the dynamic transportation of histones from the cytoplasm to the nucleus by building a ternary network with histones and karyopherins (68).

Earlier research on medicinal plants also demonstrated the potent scavenging free radicals in the extracts of *Myrtus* (89.583 $\mu\text{g/mL}$) and also the antioxidant activity of the extracts increased by an increase in the concentration of the extract (62). Low concentrations (16 $\mu\text{g/mL}$ and 32 $\mu\text{g/mL}$) of the extract resulted in the highest antioxidant activity (69). Tuberoso et al. (70) studied the synthetic structure of *Myrtus* and described the crucial oils from leaves and berries of myrtle and found the significant composites to be: α -pinene (30.0% and 28.5%), 1, 8-cineole (28.8 and 15.3%), and limonene (17.5% and 24.1%). Although many crops from the Myrtaceae family are announced to have antibacterial or antifungal activities (71, 72), very little has been reported on the antioxidant activity of this plant (73, 74).

Based on the high antioxidant activity of *Myrtus* (74)

and the results of α -pinene anticancer activity (15, 21), in silico molecular docking analysis of α -pinene revealed that α -pinene can act as a strong anticancer drug against testicular cancer (Figure 2B, C, and D and Figure 3). Thus, *Myrtus* extract can be used as a strong herbal medicine against testicular cancer without having side effects.

The placement of the expressed genes in mouse and fetus into one group showed that some of TSPY genes express only a certain stage of growth that they are different from other genes from another stage of growth (Figure 1). Also, the mouse model was used for cancer treatment by the targeted drug delivery to the different tumors (75-78). It suggests that *Myrtus* oil and extract as effective in the treatment of testicular cancer in the mouse model.

5.1. Conclusions

Docking studies of the α -pinene with TSPY showed that this ligand is a good molecule that docks well with the TSPY target. Therefore, the α -pinene molecule plays an important role in inhibiting testicular cancer. The results of the present study demonstrated that α -pinene accurately interacts with the TSPY protein target and could be developed as a promising candidate for the new anticancer agent against testicular cancer.

The outcome will be different because it depends on the purity of protein α -pinene and the interaction of α -pinene with other existing proteins, as well as the personal genotype, type of hormones, and the concentrations of them.

Footnotes

Authors' Contribution: B.F.N. designed the research and wrote the paper. R.Z.S. and A.S. helped to write the manuscript and also presented helpful ideas on the writing of the manuscript. All authors read and approved the final manuscript.

Conflict of Interests: All authors declare no conflict of interest.

Ethical Approval: No human or animals were used in the present research.

Funding/Support: University of zabol

References

- Akimoto C, Ueda T, Inoue K, Yamaoka I, Sakari M, Obara W, et al. Testis-specific protein on Y chromosome (TSPY) represses the activity of the androgen receptor in androgen-dependent testicular germ-cell tumors. *Proc Natl Acad Sci U S A*. 2010;**107**(46):19891-6. doi: [10.1073/pnas.1010307107](#). [PubMed: [21041627](#)]. [PubMed Central: [PMC2993411](#)].
- Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, Cordum HS, Hillier L, Brown LG, et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. *Nature*. 2003;**423**(6942):825-37. doi: [10.1038/nature01722](#). [PubMed: [12815422](#)].
- Giachini C, Nuti F, Turner DJ, Laface I, Xue Y, Daguin F, et al. TSPY1 copy number variation influences spermatogenesis and shows differences among Y lineages. *J Clin Endocrinol Metab*. 2009;**94**(10):4016-22. doi: [10.1210/jc.2009-1029](#). [PubMed: [19773397](#)]. [PubMed Central: [PMC3330747](#)].
- Ozbun LL, You L, Kiang S, Angdisen J, Martinez A, Jakowlew SB. Identification of differentially expressed nucleolar TGF- β 1 target (DENT1) in human lung cancer cells that is a new member of the TSPY/SET/NAP-1 superfamily. *Genomics*. 2001;**73**(2):179-93. doi: [10.1006/geno.2001.6505](#). [PubMed: [11318608](#)].
- Honecker F, Stoop H, de Krijger RR, Chris Lau YF, Bokemeyer C, Looijenga LH. Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cells. *J Pathol*. 2004;**203**(3):849-57. doi: [10.1002/path.1587](#). [PubMed: [15221945](#)].
- Lau YF, Li Y, Kido T. Role of the Y-located putative gonadoblastoma gene in human spermatogenesis. *Syst Biol Reprod Med*. 2011;**57**(1-2):27-34. doi: [10.3109/19396368.2010.499157](#). [PubMed: [21204751](#)].
- Kim HS, Takenaka O. A comparison of TSPY genes from Y-chromosomal DNA of the great apes and humans: Sequence, evolution, and phylogeny. *Am J Phys Anthropol*. 1996;**100**(3):301-9. doi: [10.1002/\(SICI\)1096-8644\(199607\)100:3<301::AID-AJPA1>3.0.CO;2-X](#). [PubMed: [8798990](#)].
- Mazeyrat S, Mitchell MJ. Rodent Y chromosome TSPY gene is functional in rat and non-functional in mouse. *Hum Mol Genet*. 1998;**7**(3):557-62. doi: [10.1093/hmg/7.3.557](#). [PubMed: [9467017](#)].
- Lau YF. Gonadoblastoma, testicular and prostate cancers, and the TSPY gene. *Am J Hum Genet*. 1999;**64**(4):921-7. doi: [10.1086/302353](#). [PubMed: [10090875](#)]. [PubMed Central: [PMC1377814](#)].
- Hildenbrand R, Schröder W, Brude E, Schepler A, König R, Stutte HJ, et al. Detection of TSPY protein in a unilateral microscopic gonadoblastoma of a Turner mosaic patient with a Y-derived marker chromosome. *J Pathol*. 1999;**189**(4):623-6. doi: [10.1002/\(SICI\)1096-9896\(199912\)189:4<623::AID-PATH475>3.0.CO;2-#](#). [PubMed: [10629567](#)].
- Haughey BP, Graham S, Brasure J, Zielezny M, Sufrin G, Burnett WS. The epidemiology of testicular cancer in upstate New York. *Am J Epidemiol*. 1989;**130**(1):25-36. doi: [10.1093/oxfordjournals.aje.a115319](#). [PubMed: [2568087](#)].
- PDQ Screening and Prevention Editorial Board. Testicular cancer screening (PDQ®): Patient version. *PDQ cancer information summaries*. USA: National Cancer Institute (US); 2018.
- Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: A review. *J Urol*. 2003;**170**(1):5-11. doi: [10.1097/01.ju.0000053866.68623.da](#). [PubMed: [12796635](#)].
- de Mesquita ML, de Paula JE, Pessoa C, de Moraes MO, Costa-Lotufo LV, Grougnet R, et al. Cytotoxic activity of Brazilian Cerrado plants used in traditional medicine against cancer cell lines. *J Ethnopharmacol*. 2009;**123**(3):439-45. doi: [10.1016/j.jep.2009.03.018](#). [PubMed: [19501276](#)].
- Matsuo AL, Figueiredo CR, Arruda DC, Pereira FV, Scutti JA, Mas-saoka MH, et al. α -Pinene isolated from *Schinus terebinthifolius* Raddi (Anacardiaceae) induces apoptosis and confers antimetastatic protection in a melanoma model. *Biochem Biophys Res Commun*. 2011;**411**(2):449-54. doi: [10.1016/j.bbrc.2011.06.176](#). [PubMed: [21756878](#)].
- Abdel-Kader M, Mahmoud AH, Motawa HM, Wahba HE, Ebrahim AY. Antitumor activity of *Urtica pilulifera* on Ehrlich ascites carcinoma in mice. *Asian J Biochem*. 2007;**2**:375-85.
- Shah TI, Sharma E, Shan GA. Anti proliferative activity of ricinus communis leaves against B16F10 melanoma induced c57bl/6 mice. *Int J Recent Sci Res*. 2015;**6**:2886-9.
- Harvey AL. Natural products in drug discovery. *Drug Discov Today*. 2008;**13**(19-20):894-901. doi: [10.1016/j.drudis.2008.07.004](#). [PubMed: [18691670](#)].
- Tariq A, Sadia S, Pan K, Ullah I, Mussarat S, Sun F, et al. A systematic review on ethnomedicines of anti-cancer plants. *Phytother Res*. 2017;**31**(2):202-64. doi: [10.1002/ptr.7551](#). [PubMed: [28093828](#)].
- Salminen A, Lehtonen M, Suuronen T, Kaarniranta K, Huuskonen J. Terpenoids: Natural inhibitors of NF- κ B signaling with anti-inflammatory and anticancer potential. *Cell Mol Life Sci*. 2008;**65**(19):2979-99. doi: [10.1007/s00018-008-8103-5](#). [PubMed: [18516495](#)].
- Chen W, Liu Y, Li M, Mao J, Zhang L, Huang R, et al. Anti-tumor effect of α -pinene on human hepatoma cell lines through inducing G2/M cell cycle arrest. *J Pharmacol Sci*. 2015;**127**(3):332-8. doi: [10.1016/j.jphs.2015.01.008](#). [PubMed: [25837931](#)].
- Ervina M; Sukardiman. A review: Melia azedarach L. as a potent anticancer drug. *Pharmacognosy Reviews*. 2018;**12**(23):94. doi: [10.4103/phrev.phrev.41.17](#).
- Nisa S, Bibi Y, Zia M, Waheed A, Chaudhary MF. Anticancer investigations on *Carissa opaca* and *Toona ciliata* extracts against human breast carcinoma cell line. *Pak J Pharm Sci*. 2013;**26**(5):1009-12. [PubMed: [24035960](#)].
- Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. *J Ethnopharmacol*. 2005;**100**(1-2):72-9. doi: [10.1016/j.jep.2005.05.011](#). [PubMed: [16009521](#)].
- Marchler-Bauer A, Derbyshire MK, Gonzales NR, Lu S, Chitsaz F, Geer LY, et al. CDD: NCBI's conserved domain database. *Nucleic Acids Res*. 2015;**43**(Database issue):D222-6. doi: [10.1093/nar/gku1221](#). [PubMed: [25414356](#)]. [PubMed Central: [PMC4383992](#)].
- Artimo P, Jonnalagedda M, Arnold K, Baratin D, Csardi G, de Castro E, et al. ExPASy: SIB bioinformatics resource portal. *Nucleic Acids Res*. 2012;**40**(Web Server issue):W597-603. doi: [10.1093/nar/gks400](#). [PubMed: [22661580](#)]. [PubMed Central: [PMC3394269](#)].
- Softberry. *ProtComp - Version 9: Program for Identification of sub-cellular localization of Eukaryotic proteins: Animal/Fungi*. Softberry; 2020. Available from: <http://www.softberry.com/berry.phtml?topic=protocompan&group=help&subgroup=proloc>.
- Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. *Proc Natl Acad Sci U S A*. 2004;**101**(30):11030-5. doi: [10.1073/pnas.0404206101](#). [PubMed: [15258291](#)]. [PubMed Central: [PMC491989](#)].
- Tamura K, Stecher G, Peterson D, Filipinski A, Kumar S. MEGA6: Molecular evolutionary genetics analysis version 6.0. *Mol Biol Evol*. 2013;**30**(12):2725-9. doi: [10.1093/molbev/mst197](#). [PubMed: [24132122](#)]. [PubMed Central: [PMC3840312](#)].

30. Hall TA. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucleic acids symposium series*. London: Information Retrieval Ltd., c1979-c2000; 1999. p. 95–8.
31. Vincze T, Posfai J, Roberts RJ. NEBcutter: A program to cleave DNA with restriction enzymes. *Nucleic Acids Res*. 2003;**31**(13):3688–91. doi: [10.1093/nar/gkg526](#). [PubMed: [12824395](#)]. [PubMed Central: [PMC168933](#)].
32. Huang X, Madan A. CAP3: A DNA sequence assembly program. *Genome Res*. 1999;**9**(9):868–77. doi: [10.1101/gr.9.9.868](#). [PubMed: [10508846](#)]. [PubMed Central: [PMC310812](#)].
33. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. *Genetics*. 1989;**123**(3):585–95. [PubMed: [2513255](#)]. [PubMed Central: [PMC1203831](#)].
34. Fu YX, Li WH. Statistical tests of neutrality of mutations. *Genetics*. 1993;**133**(3):693–709. [PubMed: [8454210](#)]. [PubMed Central: [PMC1205353](#)].
35. Simonsen KL, Churchill GA, Aquadro CF. Properties of statistical tests of neutrality for DNA polymorphism data. *Genetics*. 1995;**141**(1):413–29. [PubMed: [8536987](#)]. [PubMed Central: [PMC1206737](#)].
36. Watterson GA. On the number of segregating sites in genetical models without recombination. *Theor Popul Biol*. 1975;**7**(2):256–76. doi: [10.1016/0040-5809\(75\)90020-9](#). [PubMed: [1145509](#)].
37. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R. DnaSP, DNA polymorphism analyses by the coalescent and other methods. *Bioinformatics*. 2003;**19**(18):2496–7. doi: [10.1093/bioinformatics/btg359](#). [PubMed: [14668244](#)].
38. Tajima F. Evolutionary relationship of DNA sequences in finite populations. *Genetics*. 1983;**105**(2):437–60. [PubMed: [6628982](#)]. [PubMed Central: [PMC1202167](#)].
39. Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. *Nat Genet*. 1999;**22**(3):239–47. doi: [10.1038/10297](#). [PubMed: [10391210](#)].
40. Nei M. *Molecular evolutionary genetics*. Columbia, USA: Columbia university press; 1987.
41. Rozas J, Ferrer-Mata A, Sanchez-DelBarrio JC, Guirao-Rico S, Librado P, Ramos-Onsins SE, et al. DnaSP 6: DNA sequence polymorphism analysis of large data sets. *Mol Biol Evol*. 2017;**34**(12):3299–302. doi: [10.1093/molbev/msx248](#). [PubMed: [29029172](#)].
42. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: Protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids Res*. 2015;**43**(Database issue):D447–52. doi: [10.1093/nar/gku1003](#). [PubMed: [25352553](#)]. [PubMed Central: [PMC4383874](#)].
43. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: An automated protein homology-modeling server. *Nucleic Acids Res*. 2003;**31**(13):3381–5. doi: [10.1093/nar/gkg520](#). [PubMed: [12824332](#)]. [PubMed Central: [PMC168927](#)].
44. Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. *Nucleic Acids Res*. 2011;**39**(Web Server issue):W270–7. doi: [10.1093/nar/gkr366](#). [PubMed: [21624888](#)]. [PubMed Central: [PMC3125772](#)].
45. Lee H, Heo L, Lee MS, Seok C. GalaxyPepDock: A protein-peptide docking tool based on interaction similarity and energy optimization. *Nucleic Acids Res*. 2015;**43**(W1):W431–5. doi: [10.1093/nar/gkv495](#). [PubMed: [25969449](#)]. [PubMed Central: [PMC4489314](#)].
46. Kurcinski M, Jamroz M, Blaszczyk M, Kolinski A, Kmiecik S. CABS-dock web server for the flexible docking of peptides to proteins without prior knowledge of the binding site. *Nucleic Acids Res*. 2015;**43**(W1):W419–24. doi: [10.1093/nar/gkv456](#). [PubMed: [25943545](#)]. [PubMed Central: [PMC4489223](#)].
47. Geng C, Narasimhan S, Rodrigues JP, Bonvin AM. Information-Driven, Ensemble flexible peptide docking using HADDOCK. *Methods Mol Biol*. 2017;**1561**:109–38. doi: [10.1007/978-1-4939-6798-8_8](#). [PubMed: [28236236](#)].
48. Yang B, Lin SJ, Ren JY, Liu T, Wang YM, Li CM, et al. Molecular docking and molecular dynamics (MD) simulation of human anti-complement factor H (CFH) antibody Ab42 and CFH polypeptide. *Int J Mol Sci*. 2019;**20**(10). doi: [10.3390/ijms20102568](#). [PubMed: [31130605](#)]. [PubMed Central: [PMC6566401](#)].
49. Ben-Shimon A, Eisenstein M. Computational mapping of anchoring spots on protein surfaces. *J Mol Biol*. 2010;**402**(1):259–77. doi: [10.1016/j.jmb.2010.07.021](#). [PubMed: [20643147](#)].
50. Schueler-Furman O, London N. *Modeling Peptide-Protein Interactions: Methods and Protocols*. New York: Springer; 2017.
51. Zhang J, Liang Y, Zhang Y. Atomic-level protein structure refinement using fragment-guided molecular dynamics conformation sampling. *Structure*. 2011;**19**(12):1784–95. doi: [10.1016/j.str.2011.09.022](#). [PubMed: [22153501](#)]. [PubMed Central: [PMC3240822](#)].
52. Vriend G. What if: A molecular modeling and drug design program. *J Mol Graph*. 1990;**8**(1):52–6. doi: [10.1016/0263-7855\(90\)80070-v](#). [PubMed: [2268628](#)].
53. Vriend G, Sander C. Quality control of protein models: Directional atomic contact analysis. *J Appl Crystallogr*. 1993;**26**(1):47–60. doi: [10.1107/s0021889892008240](#).
54. Benkert P, Tosatto SC, Schomburg D. QMEAN: A comprehensive scoring function for model quality assessment. *Proteins*. 2008;**71**(1):261–77. doi: [10.1002/prot.21715](#). [PubMed: [17932912](#)].
55. Wiederstein M, Sippl MJ. ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. *Nucleic Acids Res*. 2007;**35**(Web Server issue):W407–10. doi: [10.1093/nar/gkm290](#). [PubMed: [17517781](#)]. [PubMed Central: [PMC1933241](#)].
56. Zhang Y, Skolnick J. Scoring function for automated assessment of protein structure template quality. *Proteins*. 2004;**57**(4):702–10. doi: [10.1002/prot.20264](#). [PubMed: [15476259](#)].
57. Xu J, Zhang Y. How significant is a protein structure similarity with TM-score = 0.5? *Bioinformatics*. 2010;**26**(7):889–95. doi: [10.1093/bioinformatics/btq066](#). [PubMed: [20164152](#)]. [PubMed Central: [PMC2913670](#)].
58. Bell EW, Zhang Y. DockRMSD: An open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism. *J Cheminform*. 2019;**11**(1):40. doi: [10.1186/s13321-019-0362-7](#). [PubMed: [31175455](#)]. [PubMed Central: [PMC6556049](#)].
59. Kumar MNS, Nei M, Kumar S, Nei EPPBM. *Molecular evolution and phylogenetics*. England: Oxford University Press; 2000.
60. Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. *Mol Biol Evol*. 1993;**10**(3):512–26. doi: [10.1093/oxfordjournals.molbev.a040023](#). [PubMed: [8336541](#)].
61. Pierre J, Collet J. *Dissimilarity analysis and representation for Windows (DARwin) software*. France: Cirad; 2014. Available from: <http://darwin.cirad.fr/darwin>.
62. Muto S, Senda M, Akai Y, Sato I, Suzuki T, Nagai R, et al. Relationship between the structure of SET/TAF-I β /INHAT and its histone chaperone activity. *Proc Natl Acad Sci U S A*. 2007;**104**(11):4285–90. doi: [10.1073/pnas.0603762104](#). [PubMed: [17360516](#)]. [PubMed Central: [PMC1810507](#)].
63. Park YJ, Luger K. The structure of nucleosome assembly protein 1. *Proc Natl Acad Sci U S A*. 2006;**103**(5):1248–53. doi: [10.1073/pnas.0508002103](#). [PubMed: [16432217](#)]. [PubMed Central: [PMC1345705](#)].
64. Attia M, Rachez C, Avner P, Rogner UC. Nucleosome assembly proteins and their interacting proteins in neuronal differentiation. *Arch Biochem Biophys*. 2013;**534**(1-2):20–6. doi: [10.1016/j.abb.2012.09.011](#). [PubMed: [23031499](#)].

65. Maiti R, Van Domselaar GH, Zhang H, Wishart DS. SuperPose: A simple server for sophisticated structural superposition. *Nucleic Acids Res.* 2004;**32**(Web Server issue):W590–4. doi: [10.1093/nar/gkh477](https://doi.org/10.1093/nar/gkh477). [PubMed: [15215457](https://pubmed.ncbi.nlm.nih.gov/15215457/)]. [PubMed Central: [PMC441615](https://pubmed.ncbi.nlm.nih.gov/PMC441615/)].
66. Ferretti L, Ledda A, Wiehe T, Achaz G, Ramos-Onsins SE. Decomposing the site frequency spectrum: The impact of tree topology on neutrality tests. *Genetics.* 2017;**207**(1):229–40. doi: [10.1534/genetics.116.188763](https://doi.org/10.1534/genetics.116.188763). [PubMed: [28679545](https://pubmed.ncbi.nlm.nih.gov/28679545/)]. [PubMed Central: [PMC5586374](https://pubmed.ncbi.nlm.nih.gov/PMC5586374/)].
67. Dasmeh P, Serohijos AW, Kepp KP, Shakhnovich EI. The influence of selection for protein stability on dN/dS estimations. *Genome Biol Evol.* 2014;**6**(10):2956–67. doi: [10.1093/gbe/evu223](https://doi.org/10.1093/gbe/evu223). [PubMed: [25355808](https://pubmed.ncbi.nlm.nih.gov/25355808/)]. [PubMed Central: [PMC4224349](https://pubmed.ncbi.nlm.nih.gov/PMC4224349/)].
68. Mosammaparast N, Jackson KR, Guo Y, Brame CJ, Shabanowitz J, Hunt DF, et al. Nuclear import of histone H2A and H2B is mediated by a network of karyopherins. *J Cell Biol.* 2001;**153**(2):251–62. doi: [10.1083/jcb.153.2.251](https://doi.org/10.1083/jcb.153.2.251). [PubMed: [11309407](https://pubmed.ncbi.nlm.nih.gov/11309407/)]. [PubMed Central: [PMC2169462](https://pubmed.ncbi.nlm.nih.gov/PMC2169462/)].
69. Amensour M, Sendra E, Abrini J, Pérez-Alvarez JA, Fernández-López J. Antioxidant activity and total phenolic compounds of myrtle extracts. *CYTA J Food.* 2010;**8**(2):95–101. doi: [10.1080/19476330903161335](https://doi.org/10.1080/19476330903161335).
70. Tuberoso CI, Barra A, Angioni A, Sarritzu E, Pirisi FM. Chemical composition of volatiles in Sardinian myrtle (*Myrtus communis* L.) alcoholic extracts and essential oils. *J Agric Food Chem.* 2006;**54**(4):1420–6. doi: [10.1021/jf052425g](https://doi.org/10.1021/jf052425g). [PubMed: [16478269](https://pubmed.ncbi.nlm.nih.gov/16478269/)].
71. Mansouri S, Foroumadi A, Ghaneie T, Najari AG. Antibacterial activity of the crude extracts and fractionated constituents of *Myrtus communis*. *Pharm Biol.* 2008;**39**(5):399–401. doi: [10.1076/phbi.39.5.399.5889](https://doi.org/10.1076/phbi.39.5.399.5889).
72. Bonjar GH. Antibacterial screening of plants used in Iranian folkloric medicine. *Fitoterapia.* 2004;**75**(2):231–5. doi: [10.1016/j.fitote.2003.12.013](https://doi.org/10.1016/j.fitote.2003.12.013). [PubMed: [15030933](https://pubmed.ncbi.nlm.nih.gov/15030933/)].
73. Hayder N, Abdelwahed A, Kilani S, Ammar RB, Mahmoud A, Ghedira K, et al. Anti-genotoxic and free-radical scavenging activities of extracts from (Tunisian) *Myrtus communis*. *Mutat Res.* 2004;**564**(1):89–95. doi: [10.1016/j.mrgentox.2004.08.001](https://doi.org/10.1016/j.mrgentox.2004.08.001). [PubMed: [15474415](https://pubmed.ncbi.nlm.nih.gov/15474415/)].
74. Fazeli-Nasab B, Rahnama M, Mazarei A. Correlation between antioxidant activity and antibacterial activity of nine medicinal plant extracts. *J Mazandaran Univ Med Sci.* 2017;**27**(149):63–78.
75. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. *Science.* 1998;**279**(5349):377–80. doi: [10.1126/science.279.5349.377](https://doi.org/10.1126/science.279.5349.377). [PubMed: [9430587](https://pubmed.ncbi.nlm.nih.gov/9430587/)].
76. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. *Clin Cancer Res.* 2005;**11**(2 Pt 1):728–34. [PubMed: [15701862](https://pubmed.ncbi.nlm.nih.gov/15701862/)].
77. Greish K, Fateel M, Abdelghany S, Rachel N, Alimoradi H, Bakhiet M, et al. Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer. *J Drug Target.* 2018;**26**(7):610–5. doi: [10.1080/1061186X.2017.1405427](https://doi.org/10.1080/1061186X.2017.1405427). [PubMed: [29148852](https://pubmed.ncbi.nlm.nih.gov/29148852/)].
78. Nie Y, He J, Shirota H, Trivett AL, Klinman DM; Yang, et al. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. *Sci Signal.* 2018;**11**(511). doi: [10.1126/scisignal.aan0790](https://doi.org/10.1126/scisignal.aan0790). [PubMed: [29295954](https://pubmed.ncbi.nlm.nih.gov/29295954/)].